Backing the Shot: A High-Risk, High-Reward Play on Cartesian Therapeutics' Phase 3 mRNA CAR-T Program
Cartesian Therapeutics is an under-the-radar clinical-stage immuno-oncology name running a Phase 3 program that, if positive, could validate mRNA-delivered CAR-T as a scalable alternative to autologous cell therapy. This trade idea lays out a directional long trade sized for high-risk biotech exposure, a clear entry at $6.50, a primary target at $1…